甲基丙烯酸钾盐与二乙烯苯的共聚物 | 65405-55-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 甲基丙烯酸钾盐与二乙烯苯的共聚物
• 中文别名: 聚克立林钾
• 英文名称: Potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate
• CAS: 65405-55-2
• 化学式: C14H15KO2
• 分子量: 254.37
• InChiKey: WVWZXTJUCNEUAE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.71
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• WGK Germany：
  3

文献信息

• [EN] GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY<br/>[FR] PEPTIDES DE LA SUPERFAMILLE DU GLUCAGON PRÉSENTANT UNE ACTION SUR LES RÉCEPTEURS AUX GLUCOCORTICOÏDES
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2013074910A1

  公开（公告）日：2013-05-23

  Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.

  本文提供了与GR配体结合的葡萄糖素超家族肽，这些肽能够作用于糖皮质激素受体。本文还提供了该发明的结合物的药物组合物和工具包。此外，本文还提供了治疗疾病的方法，例如代谢紊乱，如糖尿病和肥胖，包括给予该发明的结合物。
• USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
  申请人：McKinney Anthony Alexander

  公开号：US20160346249A1

  公开（公告）日：2016-12-01

  The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane compositions are metabolized by either or both MAO-A or cytochrome P450 enzymes and thus are effective in the treatment of individuals with cytochrome P450 polymorphisms or who are taking other medications that affect the cytochrome P450 pathway.

  本发明涉及（+）-1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷及其药用可接受的活性盐、多晶形态、糖基化衍生物、代谢物、溶剂合物、水合物和/或前药，以及其单独使用或与额外的精神疗法组合一起治疗受单胺神经递质影响的疾病，包括难治性个体的治疗。 （+）-1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷组合物被MAO-A或细胞色素P450酶中的任一或两者代谢，因此对患有细胞色素P450多态性或正在服用影响细胞色素P450途径的其他药物的个体进行治疗是有效的。
• PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF A LEVODOPA PRODRUG AND METHODS OF USE
  申请人：MAO Chen

  公开号：US20110111024A1

  公开（公告）日：2011-05-12

  Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms are disclosed.

  本发明揭示了（2R）-2-苯甲酰氧基丙基（2S）-2-氨基-3-（3,4-二羟基苯基）丙酸甲磺酸盐的药物组合物和口服剂型，以及通过口服给药这种药物组合物和剂型来治疗疾病的方法。
• INSULIN ANALOG DIMERS
  申请人：INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

  公开号：US20150274802A1

  公开（公告）日：2015-10-01

  Disclosed herein are insulin analog dimers having unique insulin receptor agonist activity based on insulin polypeptide sequences, the site of dimerization and the length of the dimerization linker that connects the two insulin polypeptides. In accordance with one embodiment the first and second insulin polypeptide are independently a two chain insulin analog or a single chain analog and the first and second insulin polypeptides are linked to one another via a B29-B29′, B1-C8, B1-B1 or C8-C8 linkage.

  本文披露了胰岛素类似物二聚体的独特胰岛素受体激动剂活性，基于胰岛素多肽序列，二聚化位点和连接两个胰岛素多肽的二聚化连接器的长度。根据一种实施例，第一和第二胰岛素多肽分别是双链胰岛素类似物或单链类似物，第一和第二胰岛素多肽通过B29-B29′、B1-C8、B1-B1或C8-C8连接彼此链接。
• Pharmaceutical composition which reduces or eliminates drug abuse potential
  申请人：——

  公开号：US20020187192A1

  公开（公告）日：2002-12-12

  A pharmaceutical composition which reduces or eliminates the drug abuse potential of central nervous system stimulant comprising: (a) a drug selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and (b) a gel forming polymer wherein the gel forming polymer is a polymer that forms a gel when contacted with moisture or placed in an aqueous solution. The present invention is based on the discovery that a central nervous system stimulant such as methylphenidate in combination with a gel forming polymer reduces or eliminates drug abuse potential by swelling in the presence of moisture, and thus, preventing nasal absorption and injectability of the drug.

  一种药物组合物，可减少或消除中枢神经系统兴奋剂的滥用潜力，包括：（a）从甲基苯丙胺、安非他命、甲基安非他命和其组合中选择的药物；和（b）一种形成凝胶的聚合物，其中形成凝胶的聚合物是在接触水分或置于水溶液中时形成凝胶的聚合物。本发明基于这样的发现：中枢神经系统兴奋剂，如甲基苯丙胺与形成凝胶的聚合物的组合，通过在水分存在时肿胀，从而防止药物经鼻吸收和注射，从而减少或消除药物滥用潜力。